Abstracts tagged "Therapy, complementary"

Abstract Number: 0712 • ACR Convergence 2024
Efficacy of Sacubitril/Valsartan in Patients with Systemic Sclerosis and Heart Failure: A Retrospective Analysis
Nouran Eshak¹, Mahmoud Abdelnabi², Jaxon Quillen¹, Michael Pham¹, Joseph Hentz¹ and Vivek Nagaraja¹, ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic Arizona, Phoenix, AZ
Background/Purpose: Cardiac involvement in systemic sclerosis (SSc) is common, underdiagnosed, and manifests variably. Myocardial involvement can manifest as left heart failure with preserved or reduced…
Abstract Number: 2577 • ACR Convergence 2024
Efficacy and Safety of ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: Results Through 104 Weeks in a Long-Term Extension Study
Joan Merrill¹, Amit Saxena², Martin Aringer³, Yoshiya Tanaka⁴, Xiaofeng Zeng⁵, Peter Wung⁶, Ling Cheng⁶, Thao Doan⁶, Shelly Kafka⁶, David DCruz⁷ and Kristin D'Silva⁶, ¹Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, ²NYU Grossman School of Medicine, New York, NY, ³University Medical Center and Faculty of Medicine, TU Dresden, Dresden, Germany, ⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁵Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China, ⁶AbbVie Inc., North Chicago, IL, ⁷The Louise Coote Lupus Unit, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: ABBV-599 (a combination of a selective Bruton’s tyrosine kinase inhibitor, elsubrutinib [ELS], and a selective Janus kinase inhibitor, upadacitinib [UPA]) targets a spectrum of…
Abstract Number: 1128 • ACR Convergence 2024
A Meta-Analysis of Statin Efficacy in Controlling Disease Activity in Psoriasis
Barbara Abreu Lopez¹, Ernesto Calderon Martinez², Tania Siu Xiao³, Zulma Sosa Carcamo⁴, Alejandra Maria Aleman Reyes⁵, Felix Ricardo Bonilla Bonilla⁶, María Isabel Murillo Pineda⁵, Edgar Josué Sanabria Herrera⁷, Alberto Ayala Aguilar⁸, Adreina Del Valle Rojas Marron⁹, Valentina Contreras Duran,¹⁰, Kevin J. Lopez Romero¹¹ and Marcela Garzon¹², ¹Universidad de Carabobo, Carabobo, Venezuela, ²The University of Texas Science Medical Center at Houston, Tomball, ³Thomas Jefferson University Hospital, Philadelphia, ⁴Universidad Evangélica de El Salvador, San Salvador, El Salvador, ⁵Universidad Católica de Honduras, Tegucigalpa, Honduras, ⁶Hospital Militar Central, San Salvador, El Salvador, ⁷Universidad Nacional Autónoma de Honduras, Tegucigalpa, ⁸Baylor College of Medicine, Houston, ⁹Universidad de Oriente Núcleo Anzoátegui, Barcelona, Venezuela, ¹⁰MD Anderson Cancer Center, Texas, Houston, ¹¹Universidad de El Salvador, San Salvador, El Salvador, ¹²Universidad de Los Andes, Bogotá, Colombia
Background/Purpose: Psoriasis is a chronic inflammatory skin disorder that is associated with an increased risk of cardiovascular diseases. Chronic inflammation in psoriasis can produce excessive…
Abstract Number: 1174 • ACR Convergence 2024
Effects of Electroacupuncture on Pain and Joint Deformity in Rat Models of Knee Osteoarthritis: A Study on the Differences in Acupoints Used
Hideshi Ikemoto, Oyunchimeg Chuluunbat, Takayuki Okumo, Naoki Adachi, Tadashi Hisamitsu and Masataka Sunagawa, Showa university, Shinagawa-ku, Tokyo, Japan
Background/Purpose: ADAMTS5, a member of the ADAMTS enzyme family, is a key enzyme in the degradation of cartilage in the early stages of knee osteoarthritis…
Abstract Number: L06 • ACR Convergence 2023
Improvement in Clinical and Patient-Reported Outcomes for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) 6 Months to 2 Years After Autologous Stem Cell Transplantation (ASCT)
Kathryn Torok¹, Paulina Horvei¹, Franziska Rosser¹, Kirsten Rose-felker², Vibha Sood², Adam Olsen², Nicole Hogue², Vickie Vandergrift², Lauren Farver², Devin Mcguire², Jonathan Li³, Haley Havrilla², Jessie Alexander⁴, Shawna McIntyre² and Paul Szabolcs¹, ¹University of Pittsburgh; UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ²UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Stanford Children's Hospital, Palo Alto, CA
Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is an inflammatory, fibrotic, and vasculopathic disease that causes severe multi-organ dysfunction leading to significant morbidity and early mortality.When patients…
Abstract Number: 0860 • ACR Convergence 2023
Vagus Nerve Stimulation Enhances Bone Morphology in a Rodent Model of Central Nervous System Inflammation
Chandramohan Natarajan¹, Julia Lucchino¹, David Chenoff² and Yaakov Levine¹, ¹SetPoint Medical, Valencia, CA, ²SetPoint Medical, Sausalito, CA
Background/Purpose: Electrical stimulation of the vagus nerve activates the inflammatory reflex to inhibit cytokines and decrease clinical signs and symptoms of chronic inflammatory disease such…
Abstract Number: 0862 • ACR Convergence 2023
Role of CRTAC1 as a Biomarker of Osteoarthritis
Aneta Pekacova¹, Jiri Baloun², Adela Navratilova³, Lucia Ondrejcakova⁴, Jana Zborovjanova⁴, Petr Fulin⁵, Rastislav Ballay⁶, Michal Tomcik⁷ and Ladislav Senolt⁸, ¹First faculty of medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Hlavní město Praha, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵First Department of Orthopaedics, First Faculty of Medicine of Charles University and Motol University Hospital, Prague, Czech Republic, ⁶First Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ⁷Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁸Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic
Background/Purpose: Cartilage acidic protein-1 (CRTAC1) has been recently considered a promising biomarker of osteoarthritis (OA) progression (1,2). The aim of this study is to compare…
Abstract Number: 1200 • ACR Convergence 2023
Self-Reported Effectiveness of Cannabis for Arthritis-Related Pain
Kristin Wipfler¹, Joanna Zeiger² and Kaleb Michaud³, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²Canna Research Foundation, Boulder, CO, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Pain management remains a significant challenge for individuals with rheumatic diseases (RDs), often causing patients to seek complementary or alternative treatments to traditional medications.…
Abstract Number: 1319 • ACR Convergence 2023
Real World Data on Antifibrotics in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients
Belén Atienza-Mateo¹, Ana Serrano-Combarro², Maria Martin-Lopez³, Santos Castañeda⁴, Rafael Benito Melero-Gonzalez⁵, Jesus Loarce-Martos⁶, Natalia Mena Vazquez⁷, Carmen carrasco-Cubero⁸, Carolina Diez-Morrondo⁹, David Castro-Corredor¹⁰, Tomás Vazquez-Rodriguez¹¹, andrea Garcia-Valle¹², Gema Bonilla¹³, Marina Rodriguez-lopez¹⁴, Ignacio Brana Abascal¹⁵, SARA MARIA ROJAS HERRERA¹⁶, Juan Camilo Sarmiento-Monroy¹⁷, Pablo Andujar-Brazal¹⁸, Juan Ramon De Dios¹⁹, Carmen Gonzalez-Montagut Gomez²⁰, Sergio Ordonez-Palau²¹, Anahy Maria Brandy-Garcia²², Fernando Lozano²³, Maria Lopez-Lasanta²⁴, Cristina Campos Fernández²⁵, Marta Garijo Bufort²⁶, Ivette Casafont-Sole²⁷, Calderon Goercke²⁸, Carlota Laura Iñiguez²⁹, Francisco Ortiz-Sanjuán³⁰, Emilio Giner-Serret³¹, Bryan Josue Flores Robles³², Mireia Moreno³³, Evelin Cecilia Cervantes-Perez³⁴, Diego Ferrer³⁵, Ricardo Blanco³⁶ and On behalf of the Collaborative Group Members³⁷, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ³Hospital 12 de Octubre, Madrid, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵CHU Vigo, O Carballino, Spain, ⁶Ramón y Cajal University Hospital, Madrid, Spain, ⁷IBIMA, Málaga, Spain, ⁸Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ⁹Division of Rheumatology, Hospital de León, León, Spain, ¹⁰General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, ¹¹Rheumatology, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain, ¹²Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, ¹³Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ¹⁴Division of Rheumatology, Hospital Clínico Universitario de Santiago, La Coruna, Spain, ¹⁵Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁶Division of Rheumatology, Hospital de Mérida, Mérida, Spain, ¹⁷Hospital Clínic, Barcelona, Spain, ¹⁸Division of Rheumatology, Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁹Hospital Universitario Araba, Vitoria, Spain, ²⁰H. Clínico Universitario de Valladolid, Valladolid, Spain, ²¹H. Arnau de Vilanova, Lleida, Spain, ²²Hospital Germans Trias i Pujol, Badalona, Spain, ²³Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁴Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain, ²⁵Hospital General Universitario Valencia, Valencia, Spain, ²⁶H. de Sagunto, Valencia, Italy, ²⁷Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²⁹Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁰Hospital Universitario y Politécnico La Fe, Valencia, Spain, ³¹Hospital Royo Villanova, Teruel, Spain, ³²Hospital Universitario San Pedro, Logroño, Spain, ³³Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ³⁴Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ³⁵Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁷Spanish Collaborative Group of Interstitial Lung Disease Associated with Rheumatoid Arthritis, Spain, Spain
Background/Purpose: Interstitial lung disease (ILD) is a critical complication of rheumatoid arthritis (RA). Abatacept and rituximab are the preferred disease-modifying antirheumatic drugs (DMARDs) for RA-ILD.…
Abstract Number: 1827 • ACR Convergence 2023
Revolutionizing Fibromyalgia Treatment: Exploring the Efficacy of a New FDA Cleared Photoceutical Device
Timothy Demchak¹, Ernesto Leal-Junior², Neide Ribeiro², Heliodora Casalechi², Douglas Johnson³ and Shaiane Tomazoni⁴, ¹Indiana State University, Terre Haute, IN, ²Nove de Julho University, São Paulo, Brazil, ³Multi Radiance Medical, Solon, OH, ⁴University of Bergen, Bergen, Norway
Background/Purpose: Fibromyalgia syndrome effects 2-8% of the general population and is characterized by specific tender points. FM annual economic impact $12-$14 billion.Current treatments are only…
Abstract Number: 1896 • ACR Convergence 2023
Systematic Review and Analysis of Mobile Apps for Rheumatoid Arthritis Using the Mobile Application Rating Scale
Pamela Gonzalez Manrique¹, Vinit Gilvaz², Ravinder Kaler³, Neha Batra³ and Anthony Reginato², ¹Roger Williams Medical Center, North Providence, RI, ²The Warren Alpert Medical School of Brown University, Providence, RI, ³Roger Williams Medical Center, Providence, RI
Background/Purpose: Rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized by inflammatory polyarthritis with infrequent extra-articular involvement. The management of RA typically requires frequent clinic…
Abstract Number: 1914 • ACR Convergence 2023
Intravenous Immunoglobulins in the Treatment of Idiopathic Inflammatory Myopathies in a Region of Northern Spain: Analysis by Subtypes
Cristina Corrales Selaya¹, David Martínez-Lopez², Diana Prieto-Peña¹, Fabricio Benavides¹, Jose Luis Martin-Varillas³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Sierrallana, Torrelavega, Spain, ³Hospital de Laredo, Laredo, Spain, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of diseases characterised mainly by the presence of inflammation and muscle weakness. The main subtypes of…
Abstract Number: 2015 • ACR Convergence 2023
Synergistic Effect Between Denosumab and Immune Checkpoint Inhibitors : A Retrospective Study of 268 Patients with Bone Metastases
Emmanuel Massy¹, Etienne Mabrut¹, Sabine Mainbourg² and Cyrille Confavreux¹, ¹Centre Expert des Métastases Osseuses (CEMOS) - Service de Rhumatologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université de Lyon, INSERM UMR 1033-LYOS, Lyon, France, ²Service de médecine interne et vasculaire, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, F-69495 Pierre-Bénite, Laboratoire de Biométrie et Biologie Evolutive, Université Lyon 1; CNRS, UMR 5558, 69622 Villeurbanne, Lyon, France
Background/Purpose: Bone is the third site of metastasis. Bone metastases are associated with poorer survival of patients and impaired quality of life with the occurrence…
Abstract Number: 2493 • ACR Convergence 2023
Renal Prognosis of Dialysis-dependent Patients at Baseline in ANCA-associated Vasculitis
Maxime Vignac¹, Dorian Nezam², François Grolleau³, Pauline Morel⁴, Dimitri Titeca-Beauport⁵, Stanislas Faguer⁶, alexandre Karras⁷, Justine Solignac⁸, Noémie Jourde-Chiche⁹, Francois Maurier¹⁰, Hamza Sakhi¹, Khalil El Karoui¹, Rafik Mesbah¹¹, Pierre Louis Carron¹², Vincent Audard¹, Didier Ducloux¹³, Romain Paule¹⁴, Jean-François Augusto¹⁵, Julien Aniort¹⁶, Aurélien Tiple¹⁶, Cédric Rafat¹, Xavier Puéchal¹⁷, Pierre Gobert¹⁸, Catherine Hanrotel¹⁹, Stéphane Bally²⁰, Nihal Martis²¹, Cécile-Audrey Durel²², Pascal Godmer²³, Aurélie Hummel²⁴, François Perrin²⁵, Antoine Néel²⁶, Claire De Moreuil²⁷, Tiphaine Goulenok²⁸, Dominique Guerrot²⁹, Aurelie Foucher³⁰, Alban DEROUX¹², Loic Guillevin³¹, Alexis REGENT³², Raphaël Porcher³ and Benjamin Terrier³³, ¹APHP, Paris, France, ²CH du Havre, Havre, France, ³Université Paris Cité, Paris, France, ⁴AURA Paris Plaisance, Paris, France, ⁵CHU Amiens, Amiens, France, ⁶CHU Toulouse, Toulouse, France, ⁷HEGP - APHP, Paris, France, ⁸APHM, Marseille, France, ⁹AP-HM, Marseille, France, ¹⁰Hôpitaux privés de Metz, Vaux / Frankreich, France, ¹¹Boulogne Hospital (CH), Boulogne, France, ¹²CHU de Grenoble, Grenoble, France, ¹³CHU de Besançon, Besançon, France, ¹⁴Hôpital Foch, Paris, France, ¹⁵CHU d'Angers, Angers, France, ¹⁶CHU de Clermont Ferrand, Clermont Ferrand, France, ¹⁷National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ¹⁸Clinique Rhône Durance, Avignon, France, ¹⁹CHU Brest, Brest, France, ²⁰CH Métropole Savoie, Chambery, France, ²¹CHU de Nice, Nice, France, ²²CHU Lyon, Lyon, France, ²³CH Bretagne Atlantique, Vannes, France, ²⁴CHU Necker, Paris, France, ²⁵CH Saint Nazaire, Saint Nazaire, France, ²⁶CHU de Nantes, Nantes, France, ²⁷CHU de Brest, Brest, France, ²⁸Assistance Publique Hopitaux de Paris, Paris, France, ²⁹CHU Rouen, Rouen, France, ³⁰CHU de la Réunion, Saint pierre, France, ³¹University Paris Descartes, Paris, France, ³²CHU Cochin, Université Paris Cité, Paris, France, ³³Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Renal involvement in ANCA-associated vasculitides (AAV) is an organ- and life-threatening manifestation and therefore an important prognostic factor. However, the identification of predictive factors…
Abstract Number: PP01 • ACR Convergence 2023
You Can’t Get This from a Doctor: The Role of Support Groups for Adults Aged 25-55 Living with Arthritis
Eileen Davidson, Global Healthy Living Foundation, Burnaby, BC, Canada
Background/Purpose: Living with a rheumatic condition comes with unique concerns specific to mental and social health like struggling with fatigue, anxiety, depression, and isolation, all…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].